0001178913-24-002391.txt : 20240802 0001178913-24-002391.hdr.sgml : 20240802 20240802163044 ACCESSION NUMBER: 0001178913-24-002391 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240731 FILED AS OF DATE: 20240802 DATE AS OF CHANGE: 20240802 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Toledano Miranda Jayne CENTRAL INDEX KEY: 0001686530 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38556 FILM NUMBER: 241171511 MAIL ADDRESS: STREET 1: C/O COMPASS THERAPEUTICS, INC. STREET 2: 80 GUEST STREET, SUITE 601 CITY: BOSTON STATE: MA ZIP: 02135 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Entera Bio Ltd. CENTRAL INDEX KEY: 0001638097 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: L3 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: KIRYAT HADASSAH, MINRAV BUILDING STREET 2: FIFTH FLOOR CITY: JERUSALEM STATE: L3 ZIP: 9112002 BUSINESS PHONE: 972-2-532-7151 MAIL ADDRESS: STREET 1: KIRYAT HADASSAH, MINRAV BUILDING STREET 2: FIFTH FLOOR CITY: JERUSALEM STATE: L3 ZIP: 9112002 4 1 zk2431765.xml X0508 4 2024-07-31 0 0001638097 Entera Bio Ltd. ENTX 0001686530 Toledano Miranda Jayne KIRYAT HADASSAH, MINRAV BUILDING, 5TH FLOOR JERUSALEM L3 9112002 ISRAEL 1 1 0 0 Chief Executive Officer 0 Ordinary Shares, par value NIS 0.0000769 per share 2024-07-31 4 A 0 124121 0.00 A 234873 D Stock Option (Right to Buy) 1.99 2024-07-31 4 A 0 500000 0 A 2034-04-19 Ordinary Shares, par value NIS 0.0000769 per share 500000 500000 D Represent a grant of stock-settled restricted stock units. This grant of stock-settled restricted stock units was approved by the Board of Directors (the "Board") of Entera Bio Ltd. (the "Company") on April 19, 2024, subject to approval by the Company's shareholders, which was obtained on July 31, 2024. The restricted stock units vest ratably on a quarterly basis over a one-year period that began on April 19, 2024. This grant of options was approved by the Board on April 19, 2024, subject to approval by the Company's shareholders, which was obtained on July 31, 2024. The options vest over a three-year period that commenced on April 19, 2024, with a third of the options vesting on the first anniversary of the vesting commencement date. The remaining options vest ratably on a quarterly basis over the remaining two-year period. /s/ Dana Yaacov-Garbeli, Attorney-in-Fact 2024-08-02